돼지 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2024-2032년)

Growth Factors of porcine vaccines Market

The global porcine vaccines market continues to expand as animal health, food safety, and livestock productivity gain higher priority across the world. According to the report, the market was valued at USD 1.18 billion in 2024, is projected to reach USD 1.23 billion in 2025, and is expected to grow significantly to USD 1.93 billion by 2032, driven by rising disease outbreaks in swine populations and increasing global demand for pork. In 2024, North America accounted for 45.76% of the total market share, reflecting its well-established immunization practices, strong regulatory support, and widespread awareness of zoonotic disease prevention.

Porcine vaccines play an essential role in reducing disease burden in pigs by stimulating immune responses without causing illness. These vaccines are formulated using antigens derived from viruses, bacteria, toxins, or parasites, and help farmers protect herds from devastating infectious diseases. Rising demand for animal protein and increased stocking density in commercial farms elevate the risk of disease transmission, further boosting the adoption of porcine vaccines. For example, in early 2024, swine influenza prevalence in European pig herds reached 56.6%, highlighting the need for enhanced immunization strategies to safeguard livestock health and economic stability.

Market Drivers

The growing incidence of swine diseases remains one of the strongest drivers of market growth. Diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), foot-and-mouth disease, classical swine fever, and porcine parvovirus are major threats to swine productivity. PRRS alone costs the U.S. pork industry around USD 560 million annually, due to its effects on reproduction and respiratory health. Rising global pork consumption further intensifies the need for healthier herds. In 2023, global pig meat production reached 124.67 million tons, driving greater adoption of vaccines to prevent outbreaks and ensure food safety.

Market Restraints

Despite rising demand, the market faces significant challenges due to low immunization uptake in developing countries. Limited veterinary infrastructure, low awareness among small-scale farmers, and economic constraints impede widespread vaccination. According to FAO data, almost 20% of ruminants in low-income regions die prematurely each year, with nearly half of those deaths resulting from preventable infectious diseases. Slow vaccine adoption in these regions restricts market growth and increases disease risks.

Market Opportunities

Government-led initiatives represent a major opportunity for market expansion. Several countries are launching vaccination campaigns to control swine diseases and improve herd resilience. For example, India's Livestock Health & Disease Control Program initiated a 250,000-pig Classical Swine Fever (CSF) vaccination drive for 2024-25, bolstering demand for high-quality vaccines. Growing investments in disease prevention and educational outreach programs are expected to accelerate adoption through 2032.

Market Challenges

Rapid genetic mutations in pathogens like PRRSV and Swine Influenza Virus (SIV) create difficulties in developing long-lasting and universally effective vaccines. These evolving strains challenge manufacturers to constantly update vaccine formulations. Alongside biological challenges, stringent regulatory approvals further slow product launches and increase development costs. Navigating diverse regional regulations continues to be a significant hurdle for companies planning global product expansion.

Market Trends

Technological advancements, especially genotype-specific vaccines, are shaping the future of porcine immunization. These vaccines are engineered based on pathogen genetic profiles, offering improved targeting and stronger immune responses. In October 2024, Ceva secured European approval for Cirbloc M Hyo, a PCV2d-based vaccine designed to address two of the most prevalent respiratory pathogens in swine. Such innovations enhance herd health and reduce economic losses, establishing genotype vaccines as a key growth trend through 2032.

Regional Outlook

North America

North America recorded a market size of USD 0.54 billion in 2024, driven by strong regulatory standards, high pork consumption, and advanced veterinary infrastructure. The U.S. remains the dominant contributor, supported by active R&D programs, including development of new vaccines for African Swine Fever (ASF).

Europe

Europe forms the second-largest regional market, supported by increasing pork production and rising disease prevalence. In the U.K., pig meat production rose 8.9% in 2024, highlighting the need for consistent disease prevention practices.

Asia Pacific

Asia Pacific is the fastest-growing region, driven by large pig populations in China, Japan, Vietnam, and India. National initiatives such as the NADCP program aim to improve immunization rates, supporting strong market expansion through 2032.

Latin America & Middle East/Africa

These regions are experiencing slower but steady growth due to rising pork consumption and expanding animal health programs. In Mexico, pork consumption is expected to reach 22.6 kg per person by 2033, boosting demand for disease control measures.

Conclusion

The porcine vaccines market is positioned for strong long-term growth, increasing from USD 1.18 billion in 2024 to USD 1.23 billion in 2025, and projected to reach USD 1.93 billion by 2032. With rising disease threats, technological advancements, and global initiatives targeting livestock health, demand for effective porcine vaccines will continue accelerating worldwide.

Segmentation By Product

• Inactivated
• Live Attenuated
• Recombinant
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies & Drug Stores
• Others

By Region

• North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • U.S.
  • Canada
• Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Porcine Diseases by Key Countries, By Key Countries/ Region, 2024
• 4.2. Regulatory Scenario by Key Countries/ Region, 2024
• 4.3. Overview of Vaccination for Porcine Diseases
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.6. Impact of COVID-19 on the Global Porcine Vaccines Market

5. Global Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Recombinant
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Veterinary Hospitals
  • 5.3.2. Veterinary Clinics
  • 5.3.3. Pharmacies & Drug Stores
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Recombinant
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Veterinary Hospitals
  • 6.3.2. Veterinary Clinics
  • 6.3.3. Pharmacies & Drug Stores
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Recombinant
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Veterinary Hospitals
  • 7.3.2. Veterinary Clinics
  • 7.3.3. Pharmacies & Drug Stores
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Recombinant
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Veterinary Hospitals
  • 8.3.2. Veterinary Clinics
  • 8.3.3. Pharmacies & Drug Stores
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Recombinant
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Veterinary Hospitals
  • 9.3.2. Veterinary Clinics
  • 9.3.3. Pharmacies & Drug Stores
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Porcine Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Recombinant
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Parenteral
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Veterinary Hospitals
  • 10.3.2. Veterinary Clinics
  • 10.3.3. Pharmacies & Drug Stores
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Elanco
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. HIPRA
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Boehringer Ingelheim International GmbH
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Virbac
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Merck & Co., Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Zoetis Services LLC
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Ceva
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. NEOGEN CORPORATION
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Hester Biosciences Limited
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)